My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 10
Managing RET Inhibitor Treatment-Related Adverse Events
Panelists discuss the common adverse effects for patients receiving selpercatinib or pralsetinib, strategies for managing these effects, and whether differences in the safety profiles of these drugs influence treatment choices for RET fusion–positive non–small cell lung cancer.
Video Player is loading.
- Dr Wakelee to Dr Sands: What adverse effects are common for patients receiving selpercatinib or pralsetinib?
- How do you manage these adverse effects?
- Are there any differences in safety profiles of these drugs that influence your treatment choice?
- LIBRETTO-431 Trial
- ARROW Trial
- ARROW Trial Update Annals of Oncology, 2022
- Dr Wakelee to Dr Sands: In what situations do you consider dose modifications of RET inhibitors? How often do you find this necessary in your practice?
Related Content:
